Gongwin Biopharm Holdings Co., Ltd.
Research Gongwin Biopharm Holdings Co., Ltd. (6617.TWO) on Bullrun: market cap TWD 15.32B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6617.TWO
- ExchangeTWO
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyTWD
- Market capTWD 15.32B
- Financial periodQ2 2026
- RevenueTWD 12.69M
- Net income-TWD 42.35M
- Free cash flow-TWD 61.11M
- Gross margin46.4%
Valuation Snapshot
latest market cap is TWD 15.32B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | TWD 15.32B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 TWD.
About Gongwin Biopharm Holdings Co., Ltd.
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion.
ETFs that hold Gongwin Biopharm Holdings Co., Ltd.
US-listed ETFs
Gongwin Biopharm Holdings Co., Ltd. is held by one US-listed ETF, going by the latest portfolio it filed with the SEC:
| ETF | Weight | Fee |
|---|---|---|
| State Street SPDR S&P Emerging Markets Small Cap ETF (EWX) | 0.01% | 0.65% |
Portfolios as filed with the SEC on Form N-PORT, dated June 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Gongwin Biopharm Holdings Co., Ltd.'s market cap?
Gongwin Biopharm Holdings Co., Ltd.'s market capitalization is TWD 15.32B.
What does Gongwin Biopharm Holdings Co., Ltd. do?
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion.